Artiva Biotherapeutics surges on trading debut

seekingalpha07-20

Artiva Biotherapeutics (ARTV) climbed ~25% from its initial public offering price as the cell therapy developer made its public trading debut on Friday. Following an IPO priced at $12.00 apiece, ARTV ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2452535401?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1299608214/image_1299608214.jpg","is_english":true,"pubTime":"2024-07-20 01:16","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2452535401","market":"us","top_or_hot":-1,"title":"Artiva Biotherapeutics surges on trading debut","media":"seekingalpha","content":"<div>\n<p>Artiva Biotherapeutics (ARTV) climbed ~25% from its initial public offering price as the cell therapy developer made its public trading debut on Friday. Following an IPO priced at $12.00 apiece, ARTV ...</p>\n\n<a href=\"https://seekingalpha.com/news/4125936-artiva-biotherapeutics-stock-trading-debut\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Artiva Biotherapeutics surges on trading debut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArtiva Biotherapeutics surges on trading debut\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-20 01:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4125936-artiva-biotherapeutics-stock-trading-debut><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Artiva Biotherapeutics (ARTV) climbed ~25% from its initial public offering price as the cell therapy developer made its public trading debut on Friday. Following an IPO priced at $12.00 apiece, ARTV ...</p>\n\n<a href=\"https://seekingalpha.com/news/4125936-artiva-biotherapeutics-stock-trading-debut\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AFMD","symbol_name":"Affimed NV","start_time":0,"source_url":"https://seekingalpha.com/news/4125936-artiva-biotherapeutics-stock-trading-debut","article_id":"2452535401","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1299608214/image_1299608214.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2452535401","pubTimestamp":1721409411,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Artiva Biotherapeutics  climbed ~25% from its initial public offering price as the cell therapy developer made its public trading debut on Friday. Following an IPO priced at $12.00 apiece, ARTV shares opened at $16.00 at about 12.55 PM ET, indicating a ~25% rise from the public offering price. However, the stock trended lower afterward, reaching $13.89 by about 1.05 PM ET, standing only ~16% above the IPO price. The San Diego, California-based biotech has partnered with German biotech Affimed  to develop a drug combo involving its lead asset, AlloNK, an NK cell therapy previously known as AB-101.  A Phase 1/1b trial for AlloNK is currently underway in lupus nephritis, with data expected in H1 2025. Earlier in the day, Artiva  priced its upsized public offering to sell ~13.9M shares of its common stock to raise approximately $167M in gross proceeds. Underwriters have a 30-day option to purchase up to ~2.1M in shares additionally. Artiva’s  public offering is expected to close on July 22","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"AFMD":"Affimed NV","ARTV":"Artiva Biotherapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Artiva Biotherapeutics首次交易飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AFMD":1,"ARTV":1},"content_text":"Artiva Biotherapeutics (ARTV) climbed ~25% from its initial public offering price as the cell therapy developer made its public trading debut on Friday. Following an IPO priced at $12.00 apiece, ARTV shares opened at $16.00 at about 12.55 PM ET, indicating a ~25% rise from the public offering price. However, the stock trended lower afterward, reaching $13.89 by about 1.05 PM ET, standing only ~16% above the IPO price. The San Diego, California-based biotech has partnered with German biotech Affimed (AFMD) to develop a drug combo involving its lead asset, AlloNK, an NK cell therapy previously known as AB-101.  A Phase 1/1b trial for AlloNK is currently underway in lupus nephritis, with data expected in H1 2025. Earlier in the day, Artiva (ARTV) priced its upsized public offering to sell ~13.9M shares of its common stock to raise approximately $167M in gross proceeds. Underwriters have a 30-day option to purchase up to ~2.1M in shares additionally. Artiva’s (ARTV) public offering is expected to close on July 22, 2024.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.27.0","shortVersion":"4.27.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2452535401"}